• Next Post
  • Previous Post

test

/ Uncategorized

Share the Post

About the Author

Related Posts

AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate
ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update
Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

Comments

Comments are closed.

  • Next Post
  • Previous Post